American Society of HematologyMore Insight into the Role of NETosis in Thrombotic Events in Myeloproliferative Neoplasms

A study published in Blood Advances finds that higher levels of NETosis in myeloproliferative neoplasms (MPNs) are not linked to thrombotic events. The study determined that while NETosis may play a role in facilitating thrombosis, it is not a sole causative determinant in MPN-associated thrombophilia.

American Society of HematologyYour Approach to Treating this Transplant-Ineligible Patient with Ph+ ALL?

In ASH Clinical News, Dr. Geoffrey Uy, a professor in the Oncology Division at Washington University School of Medicine in St. Louis, discusses treatment options for a transplant-ineligible patient who has Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL). The patient under review is a 61-year-old female diagnosed with Ph+ ALL who has multiple comorbidities and […]

American Medical AssociationLooking for the Optimal Endocrine Partner for ER+, HR+, ERBB2- Advanced Breast Cancer

A phase 2 clinical trial involving 486 patients examined whether fulvestrant or letrozole is more effective in treating advanced breast cancer. The results, published in JAMA Oncology, confirmed that letrozole is the preferred treatment in patients with advanced forms of breast cancer. Although fulvestrant demonstrated significant antitumor activity, it did not significantly impact the overall […]

American Medical AssociationIntervention Reduces “Death Rattle” in End-of-Life Care

Publication: JAMADesign: Multicenter, randomized, double-blind, placebo-controlled trial performed in six hospices in the Netherlands of 162 patients with a life expectancy of three or more days. Administration of subcutaneous scopolamine butylbromide, 20 mg four times a day (n = 79) or placebo (n=78) in the 157 patients included in the primary analysis.Results: A death rattle occurred in […]

American Society of HematologyA Landscape of Germ Line Mutations in a Cohort of Inherited Bone Marrow Failure (IBMF) Patients

Bone marrow failure in children and young adults is often suspected to be inherited; however, in many cases, diagnosis remains uncertain. A new study involving 179 patients (from 173 families) found that implementing precision medicine at diagnosis can improve patient management, along with the use of family counseling. This study published in Blood expands the […]

Millennium Medical PublishingManagement of Well-Differentiated Neuroendocrine Tumors

Surgery still offers the best chance of cure for patients with neuroendocrine tumors (NETs). However, for locally advanced or metastatic well-differentiated tumors, medical therapy including theranostics, targeted therapies, and chemotherapy can all play a role. Clinical Advances in Hematology & Oncology reviews the diagnosis and management of these tumors.

American Society of HematologyHow I Treat Pediatric Acute Myeloid Leukemia

In this series from Blood that tackles four cases studies, the outcomes of AML pediatric patients compared to children with ALL is explored, focusing on the emerging new treatments venetoclax (Venclexta; AbbVie/Genentech), CD33- and CD123-directed CAR T-cell therapy, CD123-directed antibody therapy, and menin inhibitors.

American Society of Clinical OncologyDose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?

The FDA has required that Amgen compare its approved KRAS-targeted therapy sotorasib (Lumakras) 960-mg dose with a 240-mg dose as one of its accelerated approval post-marketing requirements, a paradigm-shifting event that signals new scrutiny around determining the labeled dose for targeted oncology drugs, which still follow outdated maximum tolerated dose (MTD) principles in cytotoxic agents.